Compare Global X Cloud Computing ETF (CLOU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Novartis AG — how do they compare? Global X Cloud Computing ETF trades at $27.72, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| CLOU | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $168.62 |
52-Week Low | $17.60 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.28, up 3.88% in the past 24 hours. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. Recent news highlights long-term growth prospects driven by cloud computing expansion beyond AI, with top holdings like Snowflake and Datadog showing resilience.
The outlook for CLOU remains positive due to sector tailwinds and diversified cloud exposure, but risks include market volatility and competition from European tech initiatives. Investors should weigh growth potential against valuation concerns in the tech sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
